Elicera Therapeutics Receives Safety Committee Recommendation to Use Highest ELC-301 Dose as CARMA Moves Toward Phase IIa in B-cell Lymphoma

Uppsala, September 9, 2026 – Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on oncolytic viruses and CAR T-cell therapies, armed with immune-activating properties via the company’s commercially available iTANK platform, announced today that the Data Safety and Monitoring Board (DSMB) has completed its final assessment of the ongoing Phase I-part of the CARMA clinical study with the CAR T-cell therapy, ELC-301, for the treatment of B-cell lymphoma. The DSMB recommended the highest dose for continuation of the study into Phase IIa.

The dose-escalation study, conducted in collaboration with Uppsala University as the co-sponsor, consists of two parts: a dose-escalation study (Phase I) with 12 patients, which is now complete, and a dose-expansion study (Phase IIa) with 6 patients. The cell therapy ELC-301 incorporates the iTANK platform technology, which, through its parallel immune activation, aims to provide a broader and more effective attack on cancer cells.
No dose limiting toxicities have been reported in Phase I. The Data Safety and Monitoring Board (DSMB) has, after reviewing the safety data, recommended the highest dose level as the Phase IIa dose. Once approval from the Swedish Medical Products Agency (MPA) has been received, Phase IIa patients will be treated at the highest dose level.

The latest data reported from the CARMA study, press released on August 11, showed that among the eleven patients evaluated, all had achieved disease control (no disease progression) one month after treatment, and 91 percent (10/11) had obtained an objective tumor response, including six patients (55 percent) with complete metabolic response (disease-free status). Of these, four patients remained disease-free, one for at least 18 months and one for at least 12 months. The company will provide an update of preliminary efficacy data from all 12 patients in the Phase I-part of the study when the final patient in Phase I has undergone the one-month evaluation.
 

“Built on the accumulated efficacy signals we have seen so far in Phase I, the DSMB's positive recommendation strengthens our confidence in ELC-301. We can now proceed with the Phase IIa part of the CARMA study as soon as possible after MPA approval. This brings us one step closer to offering a new treatment option to patients with limited alternatives. I look forward to sharing the complete Phase I data in due course", says Elicera’s CEO, Johan Liwing.

For further information please contact:
Johan Liwing, CEO, Elicera Therapeutics AB

Phone: +46 (0) 706 70 36 75
johan.liwing@elicera.com

Certified Advisor
DNB Carnegie Investment Bank AB (publ)

About the CARMA Study
CARMA is a phase I/IIa clinical study evaluating the safety and efficacy of the CAR T-cell therapy ELC-301 in the treatment of patients with B-cell lymphoma. The study is divided into a dose-escalation phase (phase I) and a dose-expansion phase (phase IIa). Phase I primarily aims to establish the optimal dose and safety profile in up to 12 patients, while phase IIa will further evaluate the efficacy of the maximum tolerated dose in an additional six patients. Phase I is planned to include three cohorts (dosing groups), with three patients in the first and second cohorts, and six patients in the third dcohort, who are expected to receive the maximum tolerated dose. The CARMA study is being conducted at Uppsala University Hospital and Karolinska University Hospital in Huddinge.

About ELC-301
ELC-301 is a fourth-generation CAR T-cell therapy targeting the CD20 antigen, armed with the company’s iTANK platform to activate a broader and more comprehensive parallel immune response against cancer. CAR T-cells are a form of cell therapy created by genetically modifying a patient’s T-cells to express a synthetic receptor (chimeric antigen receptor, CAR). This receptor is specifically designed to target a single tumor antigen—a molecule visible on the surface of cancer cells—and enables the T-cells to locate, bind to, and destroy the cancer cells.
About the iTANK-platform
The iTANK technology platform has been developed for arming and enhancing CAR T-cells to meet two of the major challenges CAR T-cell therapies face in the treatment of solid tumors: a very diverse set of tumor antigen targets and a very hostile tumor microenvironment. The technology is used to incorporate a transgene into CAR T-cells encoding a neutrophil activating bacterial protein (NAP). NAP secreted from the CAR(NAP) T-cells has been shown to be able to enhance the function of CAR T-cells and importantly activating a parallel bystander immune response against the cancer via CD8+ killer T-cells. This is expected to lead to a broad attack against most antigen targets on cancer cells. The iTANK platform is used to enhance the company’s own CAR T-cells but can also be universally applied to other CAR T-cell therapies under development. Proof-of-concept data was published in Nature Biomedical Engineering in April 2022. The publication, titled “CAR T cells expressing a bacterial virulence factor triggers potent bystander antitumor responses in solid cancers” (DOI number: 10.1038/s41551-022-00875-5) can be found here: https://www.nature.com/articles/s41551-022-00875-5. More information about iTANK platform is available here: https://www.elicera.com/technology

About Elicera Therapeutics AB
Elicera Therapeutics AB (publ) has developed the patented gene technology platform iTANK that enables the arming of new and existing CAR T-cell therapies targeting aggressive and relapsing cancer forms. Elicera Therapeutics thereby addresses a well-defined and vast market. The company’s CAR T-cell therapies have shown a potent effect toward solid tumors which are recognized as particularly difficult to treat and constitute the majority of cancer cases. The company addresses a global multibillion market in cell therapy through its offering of non-exclusive licensing of the iTANK-platform to companies in the pharmaceutical industry. Elicera Therapeutics has four internal development projects in immune therapy that separately have the potential to generate substantial value through exclusive out-licensing agreements. The company’s share is traded on Nasdaq First North Growth Market. For additional information, visit www.elicera.com.